Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Somatostatin Receptor Positive”

57 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 57 results

Large-scale testing (Phase 3)Looking for participantsNCT06784752
What this trial is testing

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Who this might be right for
Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals 240
Early research (Phase 1)Looking for participantsNCT05687123
What this trial is testing

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Who this might be right for
Metastatic Pancreatic Neuroendocrine TumorPancreatic NeoplasmStage III Pancreatic Neuroendocrine Tumor AJCC v8+2 more
National Cancer Institute (NCI) 24
Post-approval studies (Phase 4)Ended earlyNCT00944372
What this trial is testing

Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors

Who this might be right for
Solid Tumors
Mallinckrodt 150
Large-scale testing (Phase 3)Looking for participantsNCT05918302
What this trial is testing

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Who this might be right for
Neuroendocrine TumorsLung Neuroendocrine NeoplasmThymus Neoplasms
Grupo Espanol de Tumores Neuroendocrinos 120
Early research (Phase 1)Active Not RecruitingNCT04234568
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Who this might be right for
Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)UnknownNCT02236910
What this trial is testing

An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours

Who this might be right for
Neuroendocrine Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT04711135
What this trial is testing

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorsPheochromocytomaParaganglioma
Advanced Accelerator Applications 11
Early research (Phase 1)Looking for participantsNCT06441331
What this trial is testing

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Who this might be right for
Somatostatin Receptor PositiveNETsLymphoma+5 more
ITM Solucin GmbH 20
Large-scale testing (Phase 3)Looking for participantsNCT07057622
What this trial is testing

A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs

Who this might be right for
NETS Ga68 Lu177
HTA Co., Ltd. 184
Testing effectiveness (Phase 2)Looking for participantsNCT06427798
What this trial is testing

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Who this might be right for
Somatostatin Receptor PositiveGastrointestinal Neuroendocrine TumorsPheochromocytoma+1 more
National Cancer Institute (NCI) 66
Early research (Phase 1)Looking for participantsNCT06122610
What this trial is testing

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsSomatostatin Receptor-positive Neuroendocrine Tumor
University of Wisconsin, Madison 10
Not applicableLooking for participantsNCT04949282
What this trial is testing

Spanish Series of Patients Treated With the Radionuclide Lutetium177

Who this might be right for
Neuroendocrine TumorsIntestinal NeoplasmsPancreatic Neoplasms+15 more
Sociedad Española de Medicina Nuclear e Imagen Molecular 5,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT05724108
What this trial is testing

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Who this might be right for
Metastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 94
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Testing effectiveness (Phase 2)Study completedNCT01869725
What this trial is testing

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Who this might be right for
Adult MedulloblastomaChildhood MedulloblastomaNeuroblastoma+2 more
Sue O'Dorisio 68
Not applicableStudy completedNCT01879657
What this trial is testing

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Who this might be right for
Neuroendocrine Carcinoma
Radio Isotope Therapy of America 169
Early research (Phase 1)Active Not RecruitingNCT05249114
What this trial is testing

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Providence Health & Services 6
Testing effectiveness (Phase 2)Ended earlyNCT02592707
What this trial is testing

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Who this might be right for
Neuroendocrine Tumors
Ipsen 40
Testing effectiveness (Phase 2)Study completedNCT01619865
What this trial is testing

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorsNeuroblastoma+1 more
Sue O'Dorisio 223
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05894486
What this trial is testing

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Peking University 40
Load More Results